RLX (RLX) Q4 2025 Earnings Call Transcript

RLX Technology reported Q4 net revenue of RMB 1.14 billion, up 40.3% year over year, and full-year revenue of RMB 3.96 billion, up 44%, with gross margin expanding to 31.4% from 27% and non-GAAP operating profit rising to RMB 158 million. International sales accounted for 76.5% of Q4 revenue, while Mainland China revenue grew more than 20%; management also highlighted RMB 15.73 billion in financial assets and over USD 500 million returned to shareholders. The company framed 2026 as a continued growth year, supported by Europe and Asia expansion, AI-driven efficiency gains, and broader commercialization of modern oral nicotine products.

Analysis

RLX is no longer trading like a single-country regulatory rebound story; it is increasingly a geographic barbell with domestic cash generation funding international option value. The key second-order effect is that compliance tightening in Europe and parts of Asia can actually expand RLX’s effective moat by forcing out undercapitalized gray-market operators, but that same dynamic also compresses category value in the near term as users migrate to lower-cost refillable and pod formats. The market should focus less on headline growth and more on whether RLX can convert share gains into durable gross profit per account as mix shifts across regions.

The biggest hidden positive is operating leverage from channel replication. If AI-enabled ERP and store rollout truly prevent headcount from scaling with revenue, incremental margin can stay high even if pricing normalizes; that matters because the stock’s multiple should expand only if investors believe this is a repeatable operating system rather than a one-off regulatory arb opportunity. The balance sheet also changes the equity story: capital returns are no longer a sign of excess cash alone, but a signaling mechanism that management thinks internal reinvestment can outperform only in select pockets, implying M&A and partnerships will likely be more value-accretive than broad organic capex.

Main risks are time-horizon mismatches. Europe and oral nicotine are still early, so the next 2-3 quarters will likely be noisy as distribution builds, tax changes hit, and category economics normalize; any disappointment there could offset domestic stability. The contrarian view is that consensus may be underestimating how much of the current growth is regulatory front-running rather than true end-market expansion, which means the stock is vulnerable if enforcement plateaus in China or if Western Europe tax regimes become more punitive than expected.

For now, the setup favors patient holders over momentum chasers: the earnings power looks real, but the path to validating the international franchise will require clean execution through 2026 rather than a quick re-rate.

Key Decisions for Investors

• Long RLX on a 6-12 month horizon; use pullbacks after post-earnings digestion to build a position. Base case is continued share gains and capital returns, but upside is constrained until Europe/oral nicotine scale is visible.
• Buy RLX call spreads rather than outright stock for 2H26 catalyst exposure (e.g., 9-12 month tenor). This captures upside from international expansion while limiting downside if category value compression or tax changes slow revenue.
• Pair trade: long RLX / short a basket of smaller, less-capitalized nicotine or vape competitors in Europe/Asia. The thesis is that compliance and distribution scale will widen the gap over the next 2-4 quarters.
• Avoid chasing after sharp upside moves; the near-term risk/reward is best on weakness because the market will likely demand proof that AI and channel expansion are driving margin durability, not just top-line growth.
• If management guidance for 1H26 fails to show accelerating non-China contributions, reduce exposure quickly; the stock is sensitive to any sign that the international mix is less profitable than implied by the current narrative.